Clinical Trial: Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Acute Respiratory Distress Syndrome

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07892950) titled 'Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Acute Respiratory Distress Syndrome' on Oct. 19.

Brief Summary: 1. To evaluate the safety and tolerability of CG-BM1 for the treatment of patients with Acute Respiratory Distress Syndrome.

2. To observe the preliminary effectiveness of CG-BM1 in treating Acute Respiratory Distress Syndrome patients.

Study Start Date: Jan. 04, 2023

Study Type: INTERVENTIONAL

Condition: Acute Respiratory Distress Syndrome (ARDS)

Intervention: BIOLOGICAL: CG-BM1

CG-BM1 is administered as a single dose of 1.0 x 10^6 cells/kg.

BIOLOGICAL: CG...